|
Belluscura - London-based medical device developer - Notes the jump in share price movement. Says there have been no notifiable developments since its update on Friday, when it announced the start of a strategic review to ‘strengthen its capital position’ in a bid to generate sufficient working capital. Further, that day the company provided some colour on current trading, noting renewed and robust demand for the X-PLOR portable oxygen solution during April, resulting in a record sales month of $520,000. This was despite challenges in late February and March in sourcing product. Finally, also on Friday, Belluscura said the full commercial launch of the DISCOV-R respiratory support device remained on track and is expected towards the end of the third quarter, and that the US import tariff on its portable oxygen containers remains at zero. Current stock price: 1.45 pence each, up 41% on Tuesday afternoon in London 12-month change: down 86% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
